key: cord-0287838-i15skcd8
authors: Mishra, Sumita; Hahn, Virginia S.; Sadagopan, Nandhini; Dunkerly-Ering, Brittany; Rodriguez, Susana; Sarver, Dylan C.; Ceddia, Ryan P.; Murphy, Sean; Knutsdottir, Hildur; Jani, Vivek; Ashoke, Deepthi; Oeing, Christian U.; O’Rourke, Brian; Sharma, Kavita; Gangoiti, Jon; Sears, Dorothy D.; Wong, G. William; Collins, Sheila; Kass, David A.
title: PDE9 Inhibition Activates PPARα to Stimulate Mitochondrial Fat Metabolism and Reduce Cardiometabolic Syndrome
date: 2021-02-02
journal: bioRxiv
DOI: 10.1101/2021.02.02.429442
sha: 5352f0e8ea02ae6d1f0d08600d43d82ebc77ee7e
doc_id: 287838
cord_uid: i15skcd8

Central obesity with cardiometabolic syndrome (CMS) is a major global contributor to human disease, and effective therapies are needed. Here, we show inhibiting cyclic-GMP selective phosphodiesterase-9A (PDE9-I) suppresses established diet-induced obesity and CMS in ovariectomized female and male mice. PDE9-I reduces abdominal, hepatic, and myocardial fat accumulation, stimulates mitochondrial activity in brown and white fat, and improves CMS, without altering activity or food intake. PDE9 localizes to mitochondria, and its inhibition stimulates lipolysis and mitochondrial respiration coupled to PPARα-dependent gene regulation. PPARα upregulation is required for PDE9-I metabolic efficacy and is absent in non-ovariectomized females that also display no metabolic benefits from PDE9-I. The latter is compatible with estrogen receptor-α altering PPARα chromatin binding identified by ChIPSeq. In humans with heart failure and preserved ejection fraction, myocardial expression of PPARA and its regulated genes is reduced versus control. These findings support testing PDE9-I to treat obesity/CMS in men and postmenopausal women. Summary Oral inhibition of phosphodiesterase type 9 stimulates mitochondrial fat metabolism and lipolysis, reducing central obesity without changing appetite

Nearly one out of every five humans around the globe is obese(1), and in the United States this proportion exceeds 40% (2) . The pandemic has already had a major impact on global health as obesity increases the risks for diabetes, dyslipidemia, nonalcoholic fatty liver disease, inflammatory syndromes, heart failure, and hypertension, all components of cardiometabolic syndrome (CMS)(1, 3, 4) . Human studies have shown abdominal (visceral) obesity is most pathogenic (5) , whereas metabolically active adipose tissue known as brown fat appears to be protective (6) . Obesity-related disorders exhibit a sexual dimorphism as premenopausal women are relatively protected largely due to estrogen (7, 8) , yet after menopause when visceral fat increases, so do the risks for developing CMS (9, 10) . Obesity is now a defining feature of a common syndrome known as heart failure with preserved ejection fraction or HFpEF (9, 11) , which has high morbidity and little effective therapy (10, 12) . Shortly after the international spread of a novel Sars-COV2 coronavirus in early 2020, obesity quickly emerged as an independent risk factor for worse disease and mortality with many of the mechanisms proposed being identical to those highlighted in CMS (13) . Despite its broad impact on human disease, effective obesity treatments remain limited. While diet and exercise are important, their impact is often limited in severely obese individuals given their low basal metabolic rates and exertional incapacity. Diabetes therapies such as glucagon-like and fatty acid oxidation in conjunction with PPARa stimulation. We also find a sexual dimorphism, as obese intact females lack PDE9-I associated increases in PPARaregulated genes and have no change in obesity-CMS.

To test the impact of PDE9-I on obesity-CMS, we subjected C56BL6/N mice to diet-induced obesity (DIO) for 6 months, with mild mechanical cardiac pressure-stress superimposed starting at month 5 and a week later, randomizing them to either PDE9-I or placebo (vehicle) treatment ( Figure 1a ). In OVX females, DIO resulted in substantial weight gain (100-200% over baseline) similar to that found in males (Figure S1a), and reflecting severe obesity (equivalent to a body mass index (BMI) >35 kg/m 2 in humans).

These mice had marked abdominal fat accumulation (Figure S1b), glucose intolerance (Figure S1c), and hepatic steatosis ( Figure S1d ).

Using this obesity-CMS model, we tested the impact of PDE9-I on total body fat and lean mass and metabolic dysregulation in OVX females. Mice receiving placebo continued to gain weight (median 22%) during the 8-week trial, whereas PDE9-I treated mice exhibited a net -5.6% weight decline (p=2•10 -6 , Fig 1b) . Of the 23 mice treated with PDE9-I, 14 (61%) experienced a 2% or greater decline in body weight versus 1/20 (5%) in placebo (p<0.0001). MR body composition analysis revealed that PDE9-I treated mice had less total fat mass (primarily abdominal) and unaltered lean mass (Figure 1c Importantly, PDE9-I did not significantly change food intake or activity level over placebo control. However, total body O2 consumption and CO2 production were significantly greater in PDE9-I treated mice ( Figure 1g ) without a change in core temperature ( Figure S2d ).

Age-matched males subjected to the same obesity/CMS model and then treatment protocol also displayed lower total body weight primarily due to reduced fat mass ( Figure   S3a ,S3b) and less dyslipidemia ( Figure S3c ) when provided PDE9-I. PDE9-I also did not significantly alter food intake or activity but increased both body O2 consumption and CO2 production in males ( Figure S3d ) as it did in OVX females. Figure S2a . g) Food intake, activity, and whole-body respiration in OVX mice +/-PDE9-I; (MW). O2 and CO2 consumption/production rates are normalized to mass kg* = (lean mass + fat mass*0.2) as described (31) .

Prior studies have shown PDE9 counters cardiac hypertrophy and depresses profibrotic signaling cascades in non-obese males subjected to pressure-load stress, and this efficacy is independent of NO-signaling (24) . Whereas PDE5A-I does not augment myocardial cGMP in OVX females (23, 32) , here we show PDE9-I does ( Figure S4a 

Activation of FA oxidation by PPARa manifests in brown (BAT) and white (WAT) adipose tissue by increased mitochondria biogenesis and fat oxidation. Figure 3a shows example histology of BAT from a non-obese control and obese OVX and male mice treated with placebo or PDE9-I. BAT from lean mice has a darker color due to small lipid droplets and increased mitochondria density (left panel). With obesity-CMS, BAT adipocytes in placebo-treated OVX and males were enlarged with more lipid storage (pale color). This appearance was much closer to normal with PDE9-I. BAT from PDE9-I treated mice also had increased mRNA abundance of multiple genes regulating Normalized mRNA Expression 

Figure 3 C3DC C4DC C5OH C5DC_EMA C5DC_3 C5 C8:1_1 C8:1_3 C8 C10:1_3 C12 C13_2 C14:1_1 C15OH C16OH C14 C18:1OH C16:1_2 C18:1_2 C15 C18OH C16 C17_2 C17 C16DC C18DC C21

The show PDE9-I stimulates lipolysis particularly with NP background stimulation, reducing mitochondrial lipid accumulation and morphological disruption.

We previously reported PDE9 co-localizes with the sarcoplasmic reticular (SR)

ATPase at T-tubules in cardiac myocytes in contrast to PDE5A which localizes to the Zdisk (24) . The proximity of T-tubular membranes and mitochondria in the dyadic cleft raises the possibility that PDE9 also localizes with the latter. To test this, PDE9-Flag was GFP is diffusely distributed whereas PDE9-GFP is primarily found in mitochondria.

(repeated x12/group). Lower magnification images shown in Figure S6b were higher in PDE9-I treated cells (Figure 5d ). Gain-of-function was assessed by preincubating myocytes with Adenovirus expressing either Gfp-Pde9a or GFP-Pde5a. PDE9

protein expression lowered basal and maximal respiration and ATP production, whereas these were unchanged with PDE5A overexpression (Figure 5e ). Together, these data

show PDE9 localizes to mitochondria, and that its expression inhibits respiration and ATP generation whereas its inhibition achieves the opposite.

Among the most prominent clinical syndromes combining morbid obesity and CMS is HFpEF, which now affects over half of all patients with heart failure (11) . Our RNAseq analysis of differentially expressed genes in myocardium from human HFpEF versus controls found the transcriptome is potently influenced by BMI, and identified patient subgroups with distinct signaling pathway and clinical characteristics (35) . Using this database, we now show mRNA abundance for PPARA, PPARG, and PPARGC1A is reduced by ~40% (adjusted q-score, p<1e -6 for each, Figure 6a expression only identified two patient groups (Figure 6c ), both similarly obese (Table   S1 ). PDE9A was similarly and directly correlated with PPARA abundance in each group, but Group 1 had significantly lower PPARA expression for any given PDE9A level (P=7e -8 for offset by ANCOVA). Group 1 had fewer patients with diabetes, their left ventricles were smaller with less hypertrophy, and plasma natriuretic peptide levels lower as compared to Group 2. Interestingly, Group 1 overlaps with a HFpEF subgroup we had previously identified using agnostic non-negative matrix factorization and the broad transcriptome (35) , that contained mostly females with smaller hearts and proinflammatory signaling (Table S1 ). Group 2 overlaps with a second sub-group whose hearts display expression profiles closest to that for HF with low EF (35) . These results support the relevance of PPARA downregulation in HFpEF and reveal a subgroup that may be particularly responsive to enhancement by PDE9-I.

Prior studies have shown activation of PPARa in models of DIO reduces fatty liver and can prevent development of obesity (36, 37) , while the PPARa KO mouse develops obesity gradually over many months (38) . To test if PPARa activity is required to drive the anti-obesity efficacy from PDE9-I, OVX females with obesity-CMS were Volcano plot of differential mRNA expression for genes in the KEGG-PPAR pathway.

Benjamini-Hochberg MCT -q-values on y-axis. c) Unsupervised, hierarchical heat map cluster analysis using PPARA and PDE9 genes from the human HFpEF RNAseq data yielded two HFpEF groups with reciprocal relative expression of the two genes. d)

Regression PDE9 versus PPARA expression for sub-groups identified by the cluster map.

Each group has a significant positive dependence with a similar slope but different offset (ANCOVA). e) KEGG pathway analysis from differentially expressed genes in the two HFpEF subgroups defined by relative PPARA versus PDE9 expression levels.

only PDE9-I had less total body and fat mass but no significant change in lean body mass and increased VO2 and VCO2 versus placebo, and co-inhibition of PPARa prevented these changes (Figure 7b ). Total food intake and daily activity did not significantly differ between the groups ( Figure S7a ). Compared with placebo, reduced iWAT and gWAT mass ( Figure 7c ) and improved cardiac fractional shortening (Figure 7d ) with PDE9-I were largely abrogated by concomitant PPARa blockade. Thus, the in vivo efficacy of PDE9-I on obesity-CMS required PPARa activation.

Endogenous estrogen has been found to suppress PPARa-stimulated gene expression and corresponding regulation of FA oxidation in tissue and in vivo obesity models (39) . Consistent with this, the PPARa activator fenofibrate effectively reduced DIO in males and OVX females but non-OVX (37) . These results combined with the current data showing that PPARa inhibition prevents PDE9-I from reducing obesity, led us to hypothesize a similar sex dimorphism may apply to effects from PDE9-I. This was tested in a cohort of non-OVX female mice subjected to the identical HFD-mTAC protocol. As shown in Figure 8 , PDE9-I had negligible impact on total body, fat, or lean mass (Figure 8a ), BAT adipocyte size or browning (Figure 8b ), serum lipids ( Figure   S7b ), iWAT or gWAT mass ( Figure S7c ), food intake, activity, and whole-body respiration ( Figure S7d ), or hepatic steatosis ( Figure S7e ) in non-OVX females. showing ERa co-activation particularly reduces PPARa binding to genes involved with FA metabolism (Figure 8g ). This is consistent with the mRNA analysis (Figure 8c , d) and

the lack obesity-CMS effects by PDE9-I in non-OVX mice.

This study supports the utility of a new treatment for severe obesity and associated cardiometabolic syndrome based on PDE9 inhibition. We show PDE9

localizes to mitochondria, that its suppression increases fat-metabolism and lipolysis, and reduces fat deposits in the abdomen, liver, and myocardium. Concomitant reduction of myocardial lipids particularly long-chain acylcarnitines is important as their accumulation is associated with cardiac and lipotoxicity with mitochondrial dysfunction (34) . The ability of PDE9-I to reduce fat accumulation in the liver and abdomen is also significant, as both depots are linked to worse CMS morbidity (40) . (42) and AMP activated kinase (43) . These are felt to converge on transcriptional regulators PPAR gamma co-activator 1a (PGC1a) and PPARa (14, 15) to control metabolism. PKG-dependent PPARa activation has been previously linked to mitochondrial protection against hypoxia-induced cardiac injury (19) and increased FA oxidation and catabolism in skeletal muscle (16) , though not with countering obesity. To our knowledge, none of these kinase or lipase effectors of PKG modulation have been shown to confer a sexual dimorphism on metabolic signaling. However, a sexual dimorphism has been reported for the impact of PPARa activation, as obese OVX females and males show lipolysis and reduced weight, whereas non-OVX do not (37, 44, 45) . A similar disparity in PDE9-I responses coupled to differential downstream PPARa signaling supports this factor as central to the metabolic and anti-obesity effects. Estrogen itself stimulates fat metabolism and mitochondrial oxidative respiration (8) , and its decline after menopause or OVX is associated with abdominal obesity, CMS, and reduced PPARa and PGC1a regulated signaling (7) . ER and PPARa have similar DNA binding motifs and protein partners such as RXR and coactivator PGC1a (45) , and prior studies have reported ERa protein interaction with PPARa and inhibition of latter's expression and/or function in liver cancer (46) and in apolipoprotein regulation (47 Several anti-diabetic therapies are currently being tested for weight loss. Glucagon-like peptide-1 increases insulin secretion, enhancing glucose uptake and storage as glycogen.

Its anti-obesity effects are thought to be primarily due to appetite suppression with increased satiety (59) . Sodium-glucose co-transporter-2 (SGLT2) antagonists treat diabetes and also improve morbidity and mortality from heart failure(60). They too are being studied for weight loss indications (61) , and though the mechanism remains uncertain, enhanced glucose/sodium excretion may play a role. Lastly, in late 2020, an FDA advisory committee overwhelmingly supported use of the combination of sacubitril and valsartan (neprilysin inhibitor and AT-1 receptor blocker) to treat HFpEF. If approved by the FDA, this would become the first approved therapeutic for HFpEF based on clinical-trial evidence (62) . A major mechanism of its benefit over that of AT-1 blockade is attributed to suppression of NP proteolysis by neprilysin (63) . Yet studies have not reported changes in PPARa signaling nor reduction in body weight (64) or fat transcriptomes (65) . This could be a matter of dose limitations to avoid blood pressure decline, and/or enhancing the signaling in the right tissues -something PDE9-I might provide in a synergistic manner.

Our study has several limitations. We used PDE9 pharmacological inhibition rather than gene deletion to test its role, as we wanted to generate substantial obesity and CMS before applying the intervention. Results using a global PDE9 KO mouse subjected to DIO are being presented in a separate study and also reveal less weight gain and metabolic improvement over time (66) . While our model of obesity-CMS provides insights into HFpEF, it is not a model of HFpEF as the pressure-load was mild and mice did not develop heart failure. It is a reasonable model of obesity-CMS, incorporating the two-hit approach of DIO plus cardiac pressure-load sufficient to induce pathological hypertrophy. Notably, the severity of obesity generated in females and similar weight gain in OVX and males is lacking in most prior studies. We did not show direct evidence for PDE9-I increased PKG activity as this remains hard to detect despite cGMP increase from this regulatory pathway, likely due to a membrane-localized nano-compartment in which the signaling transpires that is lost with cell/tissue lysis. Still, the molecular signatures in the myocardium are very consistent with PKG activation. Lastly, the ChipSeq analysis is preliminary in that how the two transcriptional regulators interact remains unknown, as does whether this occurs similarly in adipocytes and other cells.

However, we could find no prior similar analysis, and our results do show a striking interaction consistent with the sexual dimorphism of Ppara gene regulation we observed.

When first discovered, PDE9 expression was most readily detected in the brain, and based on this, all of the early pharmacological development of selective inhibitors was targeted to neurocognitive diseases such as schizophrenia and Alzheimer's. While effective human translation remains elusive for these indications, preclinical data in the heart as since spawned clinical trials testing the impact on heart failure. This work continues, but the safety and tolerability of multiple PDE9 inhibitors has been confirmed and has negligible impact on arterial blood pressure or heart rate. Given this, the present results suggest translation to humans with obesity and CMS is feasible, and worth pursuing.

Detailed material and methods are provided in Supplemental Materials. All statistical tests used for each data set are identified in each figure legend, along with the number of biological replicates for each group. Non-parametric models were used if a group within the experiment contained 6 or less replicates, or the distribution was not normally 

Obesity and cardiovascular disease: revisiting an old relationship

Obesity: global epidemiology and pathogenesis

Obesity Phenotypes, Diabetes, and Cardiovascular Diseases

Altered adipose tissue and adipocyte function in the pathogenesis of metabolic syndrome

Regional adiposity and heart failure with preserved ejection fraction

Brown adipose tissue is associated with cardiometabolic health

The effects of oestrogens and their receptors on cardiometabolic health

Estrogen receptor α controls metabolism in white and brown adipocytes by regulating Polg1 and mitochondrial remodeling

Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection Fraction

Pivotal Role of Excess Intra-Abdominal Adipose in the Pathogenesis of Metabolic/Obese HFpEF

Cellular and molecular pathobiology of heart failure with preserved ejection fraction

Obese Heart Failure With Preserved Ejection Fraction Phenotype: From Pariah to Central Player

COVID-19 and Severe Obesity: A Big Problem?

A heart-adipose tissue connection in the regulation of energy metabolism

The Importance of Natriuretic Peptides in Cardiometabolic Diseases

Nitrate enhances skeletal muscle fatty acid oxidation via a nitric oxide-cGMP-PPAR-mediated mechanism

Nanodomain Regulation of Cardiac Cyclic Nucleotide Signaling by Phosphodiesterases

Atrial Natriuretic Peptide: A Molecular Target of Novel Therapeutic Approaches to Cardio-Metabolic Disease

Inorganic nitrate, hypoxia, and the regulation of cardiac mitochondrial respiration-probing the role of PPARα

Stimulation of soluble guanylyl cyclase protects against obesity by recruiting brown adipose tissue

Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy

Phosphodiesterase 5 as target for adipose tissue disorders. Nitric oxide : biology and chemistry / official journal of the

PDE5 inhibitor efficacy is estrogen dependent in female heart disease

Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease

CRD-733, a Novel PDE9 (Phosphodiesterase 9) Inhibitor, Reverses Pressure Overload-Induced Heart Failure

Hemodynamic, Hormonal, and Renal Actions of Phosphodiesterase-9 Inhibition in Experimental Heart Failure

Phosphodiesterase 9a Inhibition in Mouse Models of Diastolic Dysfunction

Phosphodiesterase 9A in Brain Regulates cGMP Signaling Independent of Nitric-Oxide

Alterations in cyclic nucleotide phosphodiesterase activities in omental and subcutaneous adipose tissues in human obesity

A multicenter, double-blind

Alzheimer's disease

Indirect calorimetry in laboratory mice and rats: principles, practical considerations, interpretation and perspectives

Estrogen Receptor-α Non-Nuclear Signaling Confers Cardioprotection and Is Essential to cGMP-PDE5 Inhibition Efficacy

Increasing Fatty Acid Oxidation Prevents High-Fat Diet-Induced Cardiomyopathy Through Regulating Parkin-Mediated Mitophagy

Mitochondrial Reactive Oxygen Species in Lipotoxic Hearts Induce Post-Translational Modifications of AKAP121, DRP1, and OPA1 That Promote Mitochondrial Fission

Myocardial Gene Expression Signatures in Human Heart Failure With Preserved Ejection Fraction

The Peroxisome Proliferator-Activated Receptor α (PPARα) Agonist Pemafibrate Protects against Diet-Induced Obesity in Mice

Fenofibrate regulates obesity and lipid metabolism with sexual dimorphism

Peroxisome proliferator-activated receptor alpha-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis

Inhibition of the actions of peroxisome proliferator-activated receptor alpha on obesity by estrogen

Impact of different ectopic fat depots on cardiovascular and metabolic diseases

Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes

Selective activation of mitogen-activated protein (MAP) kinase kinase 3 and p38alpha MAP kinase is essential for cyclic AMP-dependent UCP1 expression in adipocytes

Atrial natriuretic peptide regulates lipid mobilization and oxygen consumption in human adipocytes by activating AMPK

The role of PPARalpha in lipid metabolism and obesity: focusing on the effects of estrogen on PPARalpha actions

Signaling cross-talk between peroxisome proliferator-activated receptor/retinoid X receptor and estrogen receptor through estrogen response elements

Fenofibrate induced PPAR alpha expression was attenuated by oestrogen receptor alpha overexpression in Hep3B cells

Interaction of oestrogen and peroxisome proliferatoractivated receptors with apolipoprotein(a) gene enhancers

Prevention of PKG-1α Oxidation Suppresses Antihypertrophic/Antifibrotic Effects From PDE5 Inhibition but not sGC Stimulation

RGS2 mediates cardiac compensation to pressure-overload and anti-hypertrophic effects of PDE5 inhibition

Inhibition of TRPC6 channel activity contributes to the antihypertrophic effects of natriuretic peptidesguanylyl cyclase-A signaling in the heart

PKG1-modified TSC2 regulates mTORC1 activity to counter adverse cardiac stress

Natriuretic peptides and cGMP signaling control of energy homeostasis

Metabolic actions of natriuretic peptides and therapeutic potential in the metabolic syndrome

Interplay between Obesity-Induced Inflammation and cGMP Signaling in White Adipose Tissue

Higher natriuretic peptide levels associate with a favorable adipose tissue distribution profile

Enhancing natriuretic peptide signaling in adipose tissue, but not in muscle, protects against diet-induced obesity and insulin resistance

Attenuated atrial natriuretic peptide-mediated lipolysis in subcutaneous adipocytes of obese type 2 diabetic men

Effects of fenofibrate on high-fat diet-induced body weight gain and adiposity in female C57BL/6J mice

Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities. Obesity reviews : an official journal of the International Association for the Study of Obesity

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction

Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study

Differential Effects of Sacubitril/Valsartan on Diastolic Function in Mice With Obesity-Related Metabolic Heart Disease

The effects of angiotensin receptor neprilysin inhibition by sacubitril/valsartan on adipose tissue transcriptome and protein expression in obese hypertensive patients

Core Facility for sequencing

PF-04447943 was provided by Pfizer Inc. under a material transfer agreement

The authors thank the Rodent Metabolism Core at the Center for Metabolism and ObesityResearch (JHUSOM) for indirect calorimetry and GTT, Phenotyping Core for MRI body composition analysis, Small Animal CV Phenotyping and Models Core for echocardiography imaging and analysis and pressure-overload surgery, JHU ImagingCore for electron microscopy slide preparation, JHU Deep Sequencing and Microarray